Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BGM BGM Group	$7.82 +3.9%	$9.82	$5.47 ▼ $17.17	$779.72M	1.26	65,408 shs	4,594 shs
CRBU Caribou Biosciences	$1.85 +0.5%	$1.73	$0.66 ▼ $3.00	$172.28M	2.55	1.27 million shs	1.40 million shs
MNMD Mind Medicine (MindMed)	$10.19 +3.8%	$8.52	$4.70 ▼ $10.49	$775.34M	2.49	1.10 million shs	1.74 million shs
PHAT Phathom Pharmaceuticals	$11.91 +8.8%	$9.42	$2.21 ▼ $19.71	$844.94M	0.45	1.07 million shs	1.99 million shs

5G Stocks: The Path Forward is Profitable

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BGM BGM Group	0.00%	+3.24%	-28.63%	-46.69%	+33.59%
CRBU Caribou Biosciences	0.00%	-6.57%	-21.94%	+81.37%	-17.04%
MNMD Mind Medicine (MindMed)	0.00%	+6.04%	+4.84%	+39.59%	+58.97%
PHAT Phathom Pharmaceuticals	0.00%	+16.31%	+31.60%	+196.27%	-8.24%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BGM BGM Group	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
CRBU Caribou Biosciences	2.7172 of 5 stars	3.5	5.0	0.0	0.0	1.5	1.7	0.0
MNMD Mind Medicine (MindMed)	2.8264 of 5 stars	3.6	3.0	0.0	0.0	3.1	0.8	0.6
PHAT Phathom Pharmaceuticals	2.6019 of 5 stars	3.5	1.0	0.0	0.0	1.3	4.2	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BGM BGM Group	0.00	N/A	N/A	N/A
CRBU Caribou Biosciences	3.00	Buy	$6.67	260.36% Upside
MNMD Mind Medicine (MindMed)	3.22	Buy	$24.71	142.53% Upside
PHAT Phathom Pharmaceuticals	3.00	Buy	$17.50	46.94% Upside

Current Analyst Ratings Breakdown

Latest CRBU, BGM, MNMD, and PHAT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/4/2025	MNMD Mind Medicine (MindMed)	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$25.00
8/1/2025	MNMD Mind Medicine (MindMed)	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00
6/9/2025	PHAT Phathom Pharmaceuticals	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$12.00 ➝ $17.00
6/9/2025	PHAT Phathom Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00
6/6/2025	PHAT Phathom Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$28.00

(Data available from 8/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BGM BGM Group	$25.10M	30.27	N/A	N/A	$7.34 per share	1.06
CRBU Caribou Biosciences	$9.99M	17.24	N/A	N/A	$1.78 per share	1.04
MNMD Mind Medicine (MindMed)	N/A	N/A	N/A	N/A	$2.44 per share	N/A
PHAT Phathom Pharmaceuticals	$55.25M	15.29	N/A	N/A	($5.72) per share	-2.08

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BGM BGM Group	-$1.44M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
CRBU Caribou Biosciences	-$149.10M	-$1.78	N/A	N/A	N/A	-1,800.93%	-62.35%	-49.65%	11/5/2025 (Estimated)
MNMD Mind Medicine (MindMed)	-$108.68M	-$1.53	N/A	N/A	N/A	N/A	-50.24%	-39.41%	11/6/2025 (Estimated)
PHAT Phathom Pharmaceuticals	-$334.33M	-$4.73	N/A	N/A	N/A	-289.51%	N/A	-90.40%	11/6/2025 (Estimated)

Latest CRBU, BGM, MNMD, and PHAT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/12/2025	Q2 2025	CRBU Caribou Biosciences	-$0.40	-$0.35	+$0.05	-$0.58	$1.64 million	$2.67 million
7/31/2025	Q2 2025	MNMD Mind Medicine (MindMed)	-$0.38	-$0.50	-$0.12	-$0.50	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BGM BGM Group	N/A	N/A	N/A	N/A	N/A
CRBU Caribou Biosciences	N/A	N/A	N/A	N/A	N/A
MNMD Mind Medicine (MindMed)	N/A	N/A	N/A	N/A	N/A
PHAT Phathom Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BGM BGM Group	N/A	1.82	1.45
CRBU Caribou Biosciences	N/A	6.66	6.66
MNMD Mind Medicine (MindMed)	0.22	4.98	4.98
PHAT Phathom Pharmaceuticals	N/A	2.38	2.35

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BGM BGM Group	N/A
CRBU Caribou Biosciences	77.51%
MNMD Mind Medicine (MindMed)	27.91%
PHAT Phathom Pharmaceuticals	99.01%

Insider Ownership

Company	Insider Ownership
BGM BGM Group	58.66%
CRBU Caribou Biosciences	8.28%
MNMD Mind Medicine (MindMed)	2.45%
PHAT Phathom Pharmaceuticals	23.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BGM BGM Group	298	97.22 million	40.19 million	N/A
CRBU Caribou Biosciences	100	93.12 million	85.41 million	Optionable
MNMD Mind Medicine (MindMed)	40	76.09 million	74.22 million	Optionable
PHAT Phathom Pharmaceuticals	110	70.94 million	54.63 million	Optionable

CRBU, BGM, MNMD, and PHAT Headlines

Recent News About These Companies

Wall Street Analysts Think Phathom Pharmaceuticals (PHAT) Could Surge 87.21%: Read This Before Placing a Bet

August 22 at 10:55 AM | zacks.com

Phathom Pharmaceuticals Clarifies That There Is No Reduction in Lead Shareholder’s Ownership Following Administrative Change to 13D Filing

August 20, 2025 | taiwannews.com.twT

Phathom Pharmaceuticals Clarifies That There Is No Reduction in Lead Shareholder's Ownership Following Administrative Change to 13D Filing

August 20, 2025 | globenewswire.com

Phathom Pharmaceuticals (NASDAQ:PHAT) Shares Up 4.4% - Still a Buy?

August 16, 2025 | marketbeat.com

Phathom Pharmaceuticals (PHAT) Gets a Buy from H.C. Wainwright

August 14, 2025 | theglobeandmail.com

Phathom Pharmaceuticals (PHAT) Gets a Buy from Guggenheim

August 14, 2025 | theglobeandmail.com

Phathom Pharmaceuticals’ Earnings Call Highlights Growth and Challenges

August 13, 2025 | msn.com

Phathom Pharmaceuticals Second Quarter 2025 Earnings: Revenues Beat Expectations, EPS In Line

August 9, 2025 | finance.yahoo.com

Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Q2 2025 Earnings Call Transcript

August 9, 2025 | insidermonkey.com

Phathom Pharmaceuticals (NASDAQ:PHAT) Trading 11.7% Higher - Here's What Happened

August 8, 2025 | marketbeat.com

Phathom (PHAT) Q2 Revenue Jumps 441%

August 8, 2025 | theglobeandmail.com

Phathom projects $165M–$175M 2025 revenue as GI sales focus accelerates VOQUEZNA growth

August 8, 2025 | msn.com

Phathom Pharmaceuticals, Inc. (PHAT) Q2 2025 Earnings Call Transcript

August 7, 2025 | seekingalpha.com

Phathom Pharmaceuticals, Inc. (PHAT) Reports Q2 Loss, Tops Revenue Estimates

August 7, 2025 | zacks.com

Phathom Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Updates

August 7, 2025 | globenewswire.com

Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Given Consensus Rating of "Buy" by Brokerages

August 7, 2025 | marketbeat.com

XTX Topco Ltd Invests $565,000 in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT)

August 7, 2025 | marketbeat.com

Craig-Hallum Keeps Their Buy Rating on Phathom Pharmaceuticals (PHAT)

August 6, 2025 | theglobeandmail.com

Phathom Pharmaceuticals (PHAT) to Release Earnings on Thursday

August 1, 2025 | marketbeat.com

Phathom Pharmaceuticals (NASDAQ:PHAT) Stock Price Down 7% - Here's Why

July 29, 2025 | marketbeat.com

Phathom Pharmaceuticals to Report Second Quarter 2025 Financial Results and Provide Business Update on Thursday, August 7, 2025

July 28, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRBU, BGM, MNMD, and PHAT Company Descriptions

BGM Group NASDAQ:BGM

$7.82 +0.30 (+3.92%)

Closing price 08/22/2025 03:57 PM Eastern

Extended Trading

$7.94 +0.12 (+1.59%)

As of 08/22/2025 04:31 PM Eastern

Qilian International Holding Group Limited manufactures and distributes active pharmaceutical ingredients (APIs), traditional Chinese medicine derivatives (TCMD), and other by-products in China. The company provides licorice products, including Gan Di Xin, an antitussive and expectorant medicine; Qilian Shan Licorice Extract, an ingredient for pharmaceutical companies to manufacture traditional licorice tablets; and Qilian Shan licorice liquid extract, a primary ingredient for medical preparation companies to produce compound licorice oral solutions. It offers Qilian Shan oxytetracycline tablets to prevent and treat a range of diseases in chickens, turkeys, cattle, swine, and human; and Qilian Shan oxytetracycline APIs for pharmaceutical companies to manufacture medications. In addition, the company offers TCMD products, such as Ahan antibacterial paste to treat refractory chronic skin diseases; heparin products, including heparin sodium preparations for pharmaceutical companies to produce medications for cardiovascular diseases, cerebrovascular diseases, and hemodialysis; and Zhu Xiaochang sausage casings, which are natural food products for culinary application. Further, it provides Xiongguan organic fertilizers to improve crop yield and soil's chemical properties and reduce soil compaction; and Xiongguan organic-inorganic compound fertilizers to increased plant growth. Qilian International Holding Group Limited was incorporated in 2019 and is based in Jiuquan, the People's Republic of China.

Caribou Biosciences NASDAQ:CRBU

$1.85 +0.01 (+0.54%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$1.83 -0.02 (-1.08%)

As of 08/22/2025 07:39 PM Eastern

Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma. The company also develops CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma; and CB-012, an allogeneic anti-CD371 CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.

Mind Medicine (MindMed) NASDAQ:MNMD

$10.19 +0.37 (+3.77%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$10.18 0.00 (-0.05%)

As of 08/22/2025 07:54 PM Eastern

Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder. Mind Medicine (MindMed) Inc. is headquartered in New York, New York.

Phathom Pharmaceuticals NASDAQ:PHAT

$11.91 +0.96 (+8.77%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$11.92 +0.02 (+0.13%)

As of 08/22/2025 07:39 PM Eastern

Phathom Pharmaceuticals, Inc., biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time